Rosuvastatin

Rosuvastatin

Clinical data
Pregnancy category	AU: D US: X (Contraindicated)
Routes of administration	oral
ATC code	C10AA07 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	20%
Metabolism	Liver
Elimination half-life	19 hours
Excretion	Urine / Faeces
Identifiers
IUPAC name 7-[4-(4-fluorophenyl) -6-(1-methylethyl)- 2-(methyl-methylsulfonyl-amino)- pyrimidin- 5-yl]- 3,5-dihydroxy-hept-6-enoic acid
CAS Number	287714-41-4
PubChem CID	6439133
DrugBank	APRD00546
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H28FN3O6S
Molar mass	481.539

WikiDoc Resources for Rosuvastatin
Articles
Most recent articles on Rosuvastatin Most cited articles on Rosuvastatin Review articles on Rosuvastatin Articles on Rosuvastatin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Rosuvastatin Images of Rosuvastatin Photos of Rosuvastatin Podcasts & MP3s on Rosuvastatin Videos on Rosuvastatin
Evidence Based Medicine
Cochrane Collaboration on Rosuvastatin Bandolier on Rosuvastatin TRIP on Rosuvastatin
Clinical Trials
Ongoing Trials on Rosuvastatin at Clinical Trials.gov Trial results on Rosuvastatin Clinical Trials on Rosuvastatin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Rosuvastatin NICE Guidance on Rosuvastatin NHS PRODIGY Guidance FDA on Rosuvastatin CDC on Rosuvastatin
Books
Books on Rosuvastatin
News
Rosuvastatin in the news Be alerted to news on Rosuvastatin News trends on Rosuvastatin
Commentary
Blogs on Rosuvastatin
Definitions
Definitions of Rosuvastatin
Patient Resources / Community
Patient resources on Rosuvastatin Discussion groups on Rosuvastatin Patient Handouts on Rosuvastatin Directions to Hospitals Treating Rosuvastatin Risk calculators and risk factors for Rosuvastatin
Healthcare Provider Resources
Symptoms of Rosuvastatin Causes & Risk Factors for Rosuvastatin Diagnostic studies for Rosuvastatin Treatment of Rosuvastatin
Continuing Medical Education (CME)
CME Programs on Rosuvastatin
International
Rosuvastatin en Espanol Rosuvastatin en Francais
Business
Rosuvastatin in the Marketplace Patents on Rosuvastatin
Experimental / Informatics
List of terms related to Rosuvastatin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Rosuvastatin is a member of the drug class of statins, used to treat hypercholesterolemia and related conditions, and to prevent cardiovascular disease. It is currently being marketed by the pharmaceutical company AstraZeneca as Crestor.

Dosing

Rosuvastatin is available as Crestor in tablet form (5, 10, 20, or 40 mg) for oral administration. Tablets are pink, round or oval (40 mg), biconvex, film-coated, and imprinted with "ZD4522" and tablet strength. Japanese approval is in the dose range of 2.5 mg to 20 mg; therefore, smaller dose tablet forms might also be available outside the United States. Note that 97% of worldwide sales have been at or below the 20 mg dose.

Mechanism of action

Further information: [[:Statin]]

Rosuvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, having a mechanism of action similar, yet higher efficacy, to other statins.

Indications and regulation

Rosuvastatin is approved for the treatment of elevated LDL cholesterol (dyslipidemia), total cholesterol (hypercholesterolemia) and/or triglycerides (hypertriglyceridemia).

As of 2004, rosuvastatin had been approved in 154 countries and launched in 56. Approval in the United States by the FDA came on August 12, 2003.

Effects on cholesterol levels

The effects of rosuvastatin on LDL cholesterol are dose-related. At the 10mg dose, the average LDL cholesterol reduction was found to be 46% in one trial. Increasing the dose from 10 mg to 40 mg gave a modest increase of an additional 9% absolute reduction in LDL levels (55% below baseline levels).

Debate & criticisms

Several months after its introduction in Europe, Richard Horton, the editor of the medical journal The Lancet, criticized the way Crestor had been introduced to the marketplace. "AstraZeneca's tactics in marketing its cholesterol-lowering drug, rosuvastatin, raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines," according to his editorial. The Lancet's editorial position is that the data for Crestor’s superiority relies too much on extrapolation from the lipid profile data and too little on hard clinical endpoints, which are available for other statins which had been on the market longer. The manufacturer responded by stating that few drugs had been tested so successfully in so many patients. In correspondence published in The Lancet, AstraZeneca's CEO Sir Tom McKillop called the editorial "flawed and incorrect" and criticized the journal for making "such an outrageous critique of a serious, well-studied medicine."

In 2004, the consumer interest organisation Public Citizen filed a Citizen's Petition with the FDA asking that Crestor be withdrawn from the US market. On March 11, 2005, the FDA issued a letter to Sidney M. Wolfe, M.D. of Public Citizen both (a) denying the petition and (b) providing an extensive detailed analysis of findings which demonstrated no basis for concerns about rosuvastatin compared with the other statins approved for marketing in the United States; the full text of the FDA letter is available on-line: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf.

Myopathy

As with all statins, there is a concern of rhabdomyolysis (a severe undesired side effect). The FDA has indicated that "it does not appear that the risk [of rhabdomyolysis] is greater with Crestor than with other marketed statins", but has mandated that a warning about this side effect, as well as a kidney toxicity warning, be added to the product label. However, more recent, larger and more thorough reviews have actually demonstrated both slightly lower rates of myopathy for rosuvastatin than any of the other statins available within the United States and improved kidney function with all statin use, including rosuvastatin, see below.

Regarding myopathy and potential rhabdomyolysis, recent reviews of published data on all statins marketed in the US, and reviewed by the FDA, both pre and post-approval, have found that marked rises in the serum levels of muscle CK enzymes to 10 times normal or greater, the hallmark of serious muscle problems, remain very rare, 1:10,000 to 1:20,000 individuals. (For comparison, this incidence is about identical with that for acetaminophen (paracetamol), commonly purchased as Tylenol, an OTC agent about which most people rarely worry; accept as safe)

Cerivastatin, a statin recalled in 2001, was an exception; it had a higher myopathy response. For the statins still on the market in the US, reported toxicity levels has been highest for pravastatin, simvastatin next, atorvastatin next and rosuvastatin the lowest at similar milligram doses. Yet the efficacy of these agents to change blood LDLipoproteins levels, at the same milligram doses, is the exact opposite. So, from the standpoint of the rare but serious muscle toxicity events, rosuvastatin, as of mid-2005 has turned out to have the best therapeutic index of the currently available statins.

Renal effects

Recent reviews of published trial data, focusing on renal function, on placebo vs. statin, and tracking renal function over time have shown a small but distinct effect of statins to lessen renal dysfunction, when added to treatment (compared to placebo), and to slow the progression of further renal function decline over time. All the statins have a somewhat dose related response to increase urine protein levels. Because increased urine protein has long been relied upon as a warning sign of renal glomerular dysfunction, this increase as a result of statin treatment had been feared to indicate a negative effect on renal function.

However, all current evidence, see reference 6 and others, is that the increase in urinary protein is from the renal tubular cells, not the glomeruli, and is due to cholesterol synthesis inhibition within the tubular cells and is not associated with any decline in renal function. Instead, as mentioned above, clinical experience is that renal function, especially in those with partial renal failure, actually improves slightly and the rate of further decline decreases compared with those in the same trials who were randomized to the placebo agent.

Clinical Trial Data

More recent human controlled research trial data continues to be more promising. One of the most recent was a 2 year trial of rosuvastatin treatment, the ASTEROID trial, in reported in 2006 that when several hundred people were treated with Crestor at the highest currently approved dose of 40 mg a day, IVUS showed some reversal of atherosclerotic plaque within the coronary arteries.

References

• "Annual Report and Form 20-F, Information 2004" (PDF). AstraZeneca PLC. 2005.
• "Annual Report and Form 20-F, 2003" (PDF). AstraZeneca PLC. 2004.
• McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M (2001). "Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor". Am J Cardiol. 87 (5A): 28B–32B. PMID 11256847.CS1 maint: Multiple names: authors list (link)

External links

• Crestor web site, by AstraZeneca, and their Rosuvastatin Information site providing access to clinical trial information.
• "Rosuvastatin (Crestor) Information". eMedicineHealth. 10/16/2005.
  • "What Are Some Possible Side Effects of Crestor?". eMedicineHealth. 10/16/2005.

FDA documents index

2005

• 11 March 2005: Letter from FDA to Public Citizen informing of the denial of Public Citizen's 4 March 2004 Citizen's Petition
• 8 March 2005: Letter from FDA to AstraZeneca regarding "false or misleading claims regarding the superiority of Crestor".
• 2 March 2005: FDA Public Health Advisory on Crestor (rosuvastatin), patient and healthcare provider information updated
• 2 March 2005: Letter from FDA to AstraZeneca mandating changes to prescription labeling

2004

• 21 December 2004: Letter from FDA to AstraZeneca regarding "false or misleading safety claims" in a print ad
• 4 November 2004: FDA Docket listing 2004P-0113, regarding Public Citizen's Citizens' Petition of 4 March 2004
• 15 September 2004: FDA Docket listing 2004P-0113, regarding Public Citizen's Citizens' Petition of 4 March 2004
• 1 September 2004: Letter from FDA to Public Citizen indicating that Public Citizen's 4 March 2004 Citizen's Petition is still under consideration.
• 4 June 2004: FDA Docket listing 2004P-0113, regarding Public Citizen's Citizens' Petition of 4 March 2004
• 18 May 2004: Letter from Public Citizen to FDA, update to Citizen's Petition of 4 March 2004
• 6 March 2004: FDA Docket listing 2004P-0113, regarding Public Citizen's Citizens' Petition of 4 March 2004
• 5 March 2004: Letter from FDA to Public Citizen acknowledging receipt of Citizen's Petition.
• 4 March 2004: Letter from Public Citizen to FDA petitioning for the immediate removal of Crestor from the market

2003

• 12 August 2003: Letter from FDA to AstraZeneca, approval letter
• 9 July 2003: Presentations to the Endocrinologoc (sic) and Metabolic Drugs Advisory Committee

Template:WikiDoc Sources